ClinicalTrials.gg
CompletedNCT05096403Updated Oct 30, 2025Results posted

A Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With Cold Agglutinin Disease (CAD)

A Phase 3 interventional study of Pegcetacoplan and Placebo matching Pegcetacoplan in Cold Agglutinin Disease, sponsored by Swedish Orphan Biovitrum. Completed at 44 sites in 14 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-10-30.

Sponsored by Swedish Orphan Biovitrum · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain — 2 open to participants now, 7 under way, 5 of them phase 3. Anemia, Hemolytic, Autoimmune · Spain.

Enrollment
9th of 14
24 · median 36
Started
2022
with 2 others
Phase 3
9 of 15
2 open now
Registered
10th of 15
by date
Lead sponsor
1 of 15
Swedish Orphan Biovitrum

Among the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, this one is the 9th largest by enrollment of the 14 interventional ones that give a count, is one of 3 that started in 2022, is one of 9 in phase 3, and was the 10th registered.

Anemia, Hemolytic, Autoimmune

103 studies on the registry are indexed under Anemia, Hemolytic, Autoimmune; 39 are open to participants now.

Browse Anemia, Hemolytic, Autoimmune studies →

Open to participants now

2 of the 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 24 Anemia, Hemolytic, Autoimmune studies recruiting now, 12 (50%) set no upper age limit and 10 (42%) stop at 75 or younger; 5 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Anemia, Hemolytic, Autoimmune with a site in Spain, or all of them as a file.
02

Study summary

The purpose of the study is to determine the efficacy of pegcetacoplan administration compared to placebo in increasing hemoglobin (Hgb) level from baseline and avoiding transfusion in participants with primary cold agglutinin disease (CAD).

Read the detailed description

This is a blind (actual treatment not disclosed to Investigator or participant) study to study pegcetacoplan in people with cold agglutinin disease. The study will consist of a 4-week screening period where selected tests will be conducted to ensure that the patient is eligible to participate in the study, followed by Part A, a 24-week blinded treatment period where the participants will receive either pegcetacoplan or a placebo treatment, looking like pegcetacoplan but with no effect. After this period, the participants will move into Part B, a 24-week period where they will all receive pegcetacoplan. Part C is a 48-week maintenance period with pegcetacoplan for all participants. After the end of treatment participants will undergo a safety follow visit about 8 weeks after last dose.

All eligible study participants will receive pegcetacoplan or placebo treatment, administered via subcutaneous infusion twice a week at home. The subcutaneous infusion requires two small needles to be inserted into the fatty layer of tissue under the skin and the investigational medication will flow into the body. Study participants and/or caregivers will be trained on home administration of pegcetacoplan.

03

Conditions studied

  • Cold Agglutinin Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age 18 years or older.
  2. Diagnosis of primary CAD.
  3. level ≤ 9 g/dL.
  4. Documented results from bone marrow within 1 year of screening
  5. Either have vaccination against Streptococcus pneumoniae, Neisseria meningitidis (Types A, C, W, Y, and B), and Haemophilus influenzae (Type B) within 2 years prior to screening or agree to receive vaccination during screening.
  6. Women of (WOCBP), defined as any women who have experienced menarche and who are NOT permanently sterile or , must have a negative pregnancy test at screening and agree to use protocol-defined methods of for the duration of the study and 8 weeks after their last medicinal product (IMP) dose.
  7. Men must agree to the following for the duration of the study and 8 weeks after their last IMP dose:

    1. Avoid fathering a child.
    2. Use protocol-defined methods of contraception.
    3. Refrain from donating sperm.
  8. Willing and able to give written .

Exclusion criteria

Exclusion Criteria:

  1. Have received other anti-complement therapies (approved or ) within 5 half-lives of the agent prior to randomization.
  2. Treatment with rituximab monotherapy within 12 weeks prior to randomization, or rituximab combination therapies (e.g., with bendamustine, fludarabine, other cytotoxic drugs or ibrutinib) within 16 weeks prior to randomization.
  3. Diagnosis of systemic lupus erythematosus or other diseases with antinuclear antibodies.
  4. History of an aggressive lymphoma or presence of a lymphoma requiring therapy.
  5. Have received an organ transplant.
  6. Cold agglutinin syndrome secondary to Mycoplasma pneumoniae, Epstein-Barr virus or other specific causative infection.
  7. Presence or suspicion of liver dysfunction as indicated by elevated (ALT) > 2.5 x (ULN), or direct levels > 2 x ULN.
  8. Inability to cooperate with study procedures.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Pegcetacoplan Double Blind During Part A

    1080 mg, subcutaneous injection, twice weekly

    Drug: Pegcetacoplan

  • Placebo comparator
    Placebo Matching Pegcetacoplan-Double-blind During Part A

    Sodium acetate, subcutaneous injection, twice weekly

    Drug: Placebo matching Pegcetacoplan

  • Active comparator
    Open-label Pegcetacoplan During Parts B and C

    1080 mg, subcutaneous injection, twice weekly

    Drug: Pegcetacoplan

  • Placebo comparator
    Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Parts B&C

    Sodium acetate, subcutaneous injection, twice weekly

    Drug: Placebo matching Pegcetacoplan

Interventions

  • Pegcetacoplan taken twice weekly as subcutaneous injection

    Also known as: Aspaveli, Empaveli

  • DrugPlacebo matching Pegcetacoplan

    Placebo matching pegcetacoplan taken twice weekly as subcutaneous injection

06

What researchers measure

Primary outcomes

  1. Number of Patients Achieving a Response (R) at Week 24

    A participant was considered to have a response if the Hgb level increased greater than or equal to (\>=) 1.5 gram per deciliter (g/dL) from baseline and this increase was maintained from Week 16 through Week 24 in absence of blood transfusion from Week 5 through Week 24.

    Time frame: Week 24

Secondary outcomes

  1. Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from Baseline to Week 24 in Hemoglobin (Hgb) level.

    Time frame: Week 24

  2. Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A

    Percentage of patients who did not receive a blood transfusion between Week 5 and Week 24 was assessed

    Time frame: Week 24

  3. Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much. Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia.The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale. FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items,Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 item

    Time frame: Week 24

  4. Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A

    Number of blood transfusions received between Week 5 and Week 24 were assessed.

    Time frame: Week 24

  5. Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from baseline to Week 24 in Lactate dehydrogenase (LDH) levels

    Time frame: Week 24

  6. Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Haptoglobin level

    Time frame: Week 24

  7. Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Indirect bilirubin level

    Time frame: Week 24

  8. Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Absolute reticulocyte counts (ARC).

    Time frame: Week 24

  9. Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs

    * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) change from baseline to Week 24 in D-dimer levels.

    Time frame: Week 24

  10. Normalization of Markers of Hemolysis (LDH) at Week 24-Part A

    Percentage of patients with LDH level within normal ranges and with an abnormal value at baseline.

    Time frame: Week 24

  11. Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A

    Percentage of patients with Indirect Bilirubin level within normal ranges and with an abnormal value at baseline.

    Time frame: Week 24

  12. Normalization of Markers of Hemolysis (ARC) at Week 24-Part A

    Percentage of patients with ARC level within normal ranges and with an abnormal value at baseline.

    Time frame: Week 24

  13. Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A

    Percentage of patients with haptoglobin level within normal ranges and with an abnormal value at baseline.

    Time frame: Week 24

  14. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A

    Percentage of patients with haptoglobin level normalization during the initial 24 weeks of the study

    Time frame: Week 24

  15. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A

    Percentage of patients with Hemoglobin level normalization during the initial 24 weeks of the study

    Time frame: Week 24

  16. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A

    Percentage of patients with LDH level normalization during the initial 24 weeks of the study

    Time frame: Week 24

  17. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A

    Percentage of patients with Indirect Bilirubin level normalization during the initial 24 weeks of the study

    Time frame: Week 24

  18. Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A

    Percentage of patients with ARC level normalization during the initial 24 weeks of the study

    Time frame: Week 24

  19. Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A

    Number of PRBC units transfused from Week 5 and Week 24 was assessed

    Time frame: Week 5 to Week 24

  20. Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

    Time frame: Week 24

  21. Change From Baseline to Week 24 in SF-12-Part A in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange. SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean=50, SD=10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores=better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

    Time frame: Week 24

  22. Change From Baseline to Week 24 in EQ-5D-5L Questionnaire -Part A in the Absence of Intercurrent Events (ICEs)

    The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Time frame: Week 24

  23. Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Hemoglobin (Hgb) level.

    Time frame: Week 48

  24. Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in LDH level.

    Time frame: Week 48

  25. Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Haptoglobin level

    Time frame: Week 48

  26. Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Indirect Bilirubin level.

    Time frame: Week 48

  27. Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in Absolute reticulocyte counts (ARC).

    Time frame: Week 48

  28. Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in D-dimer levels.

    Time frame: Week 48

  29. Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug and plasma exchange. The FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much.Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia. The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale.FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items, Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 items

    Time frame: Week 48

  30. Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

    Time frame: Week 48

  31. Change From Baseline to Week 48 in EQ-5D-5L-Part B in the Absence of Intercurrent Events (ICEs).

    The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

    Time frame: Week 48

  32. Change From Baseline to Week 48 in SF-12-Part B in the Absence of Intercurrent Events (ICEs).

    The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean = 50, SD =10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores = better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

    Time frame: Week 48

07

Results

Posted Oct 30, 2025

Participant flow

Double-blind (Part A)
Participant flow — Double-blind (Part A)
MilestonePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Started168
Completed147
Not completed21
Open-label treatment (Part B)
Participant flow — Open-label treatment (Part B)
MilestonePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Started147
Completed83
Not completed64
Open-label maintenance period (Part C)
Participant flow — Open-label maintenance period (Part C)
MilestonePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Started83
Completed00
Not completed83

Outcome measures

PrimaryNumber of Patients Achieving a Response (R) at Week 24

A participant was considered to have a response if the Hgb level increased greater than or equal to (\>=) 1.5 gram per deciliter (g/dL) from baseline and this increase was maintained from Week 16 through Week 24 in absence of blood transfusion from Week 5 through Week 24.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Patients Achieving a Response (R) at Week 24
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Number of Patients Achieving a Response (R) at Week 2482
SecondaryChange From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from Baseline to Week 24 in Hemoglobin (Hgb) level.

Time frame:
Week 24
Reported as:
Least squares mean · grams per deciliter (g/dL)
Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).
grams per deciliter (g/dL)Pegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in Hemoglobin (Hgb) Level-Part A in the Absence of Intercurrent Events (ICEs).2.85 ± 0.3061.36 ± 0.278
SecondaryNumber of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A

Percentage of patients who did not receive a blood transfusion between Week 5 and Week 24 was assessed

Time frame:
Week 24
Reported as:
Count of participants · Participants
Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Number of Patients Achieving Transfusion Avoidance From Week 5 to Week 24-Part A12 (-0.374 to 0.691)5 (0 to 0)
SecondaryChange From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much. Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia.The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale. FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items,Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 item

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)
Units on a scalePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in FACT-An Scale Score (Quality of Life)-Part A in the Absence of Intercurrent Events (ICEs)20.67 ± 19.17516.40 ± 37.246
SecondaryNumber of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A

Number of blood transfusions received between Week 5 and Week 24 were assessed.

Time frame:
Week 24
Reported as:
Mean · Number of transfusions
Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A
Number of transfusionsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Number of Packed Red Blood Cell Transfusions Received by Patients From Week 5 to Week 24-Part A1.5 ± 3.621.1 ± 2.80
SecondaryChange From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) Mean change from baseline to Week 24 in Lactate dehydrogenase (LDH) levels

Time frame:
Week 24
Reported as:
Mean · U/L
Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)
U/LPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in LDH Levels-Part A in the Absence of Intercurrent Events (ICEs)-251.73 ± 211.312-82.00 ± 138.477
SecondaryChange From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Haptoglobin level

Time frame:
Week 24
Reported as:
Mean · g/L
Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)
g/LPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in Haptoglobin Levels-Part A in the Absence of Intercurrent Events (ICEs)0.31 ± 0.4930.01 ± 0.020
SecondaryChange From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Indirect bilirubin level

Time frame:
Week 24
Reported as:
Mean · µmol/L
Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)
µmol/LPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in Indirect Bilirubin-Part A in the Absence of Intercurrent Events (ICE)-31.55 ± 23.3408.20 ± 19.325
SecondaryChange From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 24 in Absolute reticulocyte counts (ARC).

Time frame:
Week 24
Reported as:
Mean · 10^9 cells/L
Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)
10^9 cells/LPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in ARC-Part A in the Absence of Intercurrent Events (ICEs)-41.17 ± 62.438-37.96 ± 19.891
SecondaryChange From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs

* Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange) change from baseline to Week 24 in D-dimer levels.

Time frame:
Week 24
Reported as:
Mean · µg/L FEU
Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs
µg/L FEUPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in D-dimer Levels-Part A in the Absence of Intercurrent Events (ICEs-698.70 ± 927.480-1722.75 ± 3089.162
SecondaryNormalization of Markers of Hemolysis (LDH) at Week 24-Part A

Percentage of patients with LDH level within normal ranges and with an abnormal value at baseline.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Normalization of Markers of Hemolysis (LDH) at Week 24-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Normalization of Markers of Hemolysis (LDH) at Week 24-Part A51
SecondaryNormalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A

Percentage of patients with Indirect Bilirubin level within normal ranges and with an abnormal value at baseline.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Normalization of Markers of Hemolysis (Indirect Bilirubin) at Week 24-Part A91
SecondaryNormalization of Markers of Hemolysis (ARC) at Week 24-Part A

Percentage of patients with ARC level within normal ranges and with an abnormal value at baseline.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Normalization of Markers of Hemolysis (ARC) at Week 24-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Normalization of Markers of Hemolysis (ARC) at Week 24-Part A42
SecondaryNormalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A

Percentage of patients with haptoglobin level within normal ranges and with an abnormal value at baseline.

Time frame:
Week 24
Reported as:
Count of participants · Participants
Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Normalization of Markers of Hemolysis (Haptoglobin) at Week 24-Part A40
SecondaryCount and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A

Percentage of patients with haptoglobin level normalization during the initial 24 weeks of the study

Time frame:
Week 24
Reported as:
Count of participants · Participants
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Haptoglobin Levels-Part A70
SecondaryCount and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A

Percentage of patients with Hemoglobin level normalization during the initial 24 weeks of the study

Time frame:
Week 24
Reported as:
Count of participants · Participants
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Hemoglobin Levels-Part A70
SecondaryCount and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A

Percentage of patients with LDH level normalization during the initial 24 weeks of the study

Time frame:
Week 24
Reported as:
Count of participants · Participants
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for LDH Levels-Part A62
SecondaryCount and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A

Percentage of patients with Indirect Bilirubin level normalization during the initial 24 weeks of the study

Time frame:
Week 24
Reported as:
Count of participants · Participants
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for Indirect Bilirubin Levels-Part A111
SecondaryCount and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A

Percentage of patients with ARC level normalization during the initial 24 weeks of the study

Time frame:
Week 24
Reported as:
Count of participants · Participants
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A
ParticipantsPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Count and Percentage of Patients With a First Normalization From Baseline by Week 24 for ARC Levels-Part A93
SecondaryNumber of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A

Number of PRBC units transfused from Week 5 and Week 24 was assessed

Time frame:
Week 5 to Week 24
Reported as:
Mean · Number of PRBC units transfused
Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A
Number of PRBC units transfusedPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Number of Packed Red Blood Cell Units Transfused From Week 5 to Week 24-Part A2.47 ± 5.9441.88 ± 4.549
SecondaryChange From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

Time frame:
Week 24
Reported as:
Mean · Units on a scale
Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)
Units on a scalePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Change From Baseline to Week 24 in FACIT-F Subscale Score-Part A in the Absence of Intercurrent Events (ICEs)9.73 ± 11.0288.80 ± 18.130
SecondaryChange From Baseline to Week 24 in SF-12-Part A in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange. SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean=50, SD=10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores=better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in SF-12-Part A in the Absence of Intercurrent Events (ICEs)
units on a scalePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Physical Component Score at Week 244.95 ± 7.9654.46 ± 11.867
Mental Component Score at Week 245.53 ± 9.9352.50 ± 9.777
SecondaryChange From Baseline to Week 24 in EQ-5D-5L Questionnaire -Part A in the Absence of Intercurrent Events (ICEs)

The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

Time frame:
Week 24
Reported as:
Mean · units on a scale
Change From Baseline to Week 24 in EQ-5D-5L Questionnaire -Part A in the Absence of Intercurrent Events (ICEs)
units on a scalePegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part A
Mobility-Part A0.50 ± 1.0870.00 ± 1.633
Self-care-Part A0.00 ± 0.4471.00 ± 1.414
Usual activities-Part A0.58 ± 0.6690.00 ± 0.816
Pain/Discomfort-Part A0.25 ± 0.866-0.75 ± 1.258
Anxiety/Depression-Part A0.33 ± 0.4920.00 ± 0.816
SecondaryChange From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Hemoglobin (Hgb) level.

Time frame:
Week 48
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).
grams per deciliter (g/dL)Open-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in Hemoglobin (Hgb) Level-Part B in the Absence of Intercurrent Events (ICEs).3.00 ± 2.1013.35 ± 0.995
SecondaryChange From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in LDH level.

Time frame:
Week 48
Reported as:
Mean · U/L
Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).
U/LOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in LDH Level-Part B in the Absence of Intercurrent Events (ICEs).-220.25 ± 168.347-259.25 ± 52.258
SecondaryChange From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Haptoglobin level

Time frame:
Week 48
Reported as:
Mean · grams per deciliter (g/dL)
Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).
grams per deciliter (g/dL)Open-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in Haptoglobin Level-Part B in the Absence of Intercurrent Events (ICEs).0.18 ± 0.2380.69 ± 0.262
SecondaryChange From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from Baseline to Week 48 in Indirect Bilirubin level.

Time frame:
Week 48
Reported as:
Mean · µmol/L
Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).
µmol/LOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in Indirect Bilirubin Level-Part B in the Absence of Intercurrent Events (ICEs).-40.19 ± 28.546-33.43 ± 25.237
SecondaryChange From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in Absolute reticulocyte counts (ARC).

Time frame:
Week 48
Reported as:
Mean · 10^9 cells/L
Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)
10^9 cells/LOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in ARC-Part B in the Absence of Intercurrent Events (ICEs)-39.64 ± 55.966-118.20 ± 73.076
SecondaryChange From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). Mean change from baseline to Week 48 in D-dimer levels.

Time frame:
Week 48
Reported as:
Mean · µg/L FEU
Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).
µg/L FEUOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in D-dimer Levels-Part B in the Absence of Intercurrent Events (ICEs).-596.63 ± 937.910-3595.00 ± 4879.037
SecondaryChange From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug and plasma exchange. The FACT-An is used to measure quality of life (QoL) in patients with anemia. Each item is rated on a 5-point Likert scale:0=Not at all, 1=A little bit ,2=Somewhat, 3=Quite a bit, 4=Very much.Some items are reverse scored. Higher scores in this scale denote a better QoL with less impact of anemia. The total FACT-An scale score ranges from 0 to 160. The total score gives a comprehensive view of a patient's well-being. It combines the FACT-G with an Anemia subscale.FACT-G (27 items):Physical Well-Being (PWB) and Social/Family Well-Being (SWB) 14 items in total, Emotional Well-Being (EWB)-6 items, Functional Well-Being (FWB)-7 items, Anemia Subscale (AnS): 13 items. Total FACT-An score=FACT-G + Anemia Subscale=40 items

Time frame:
Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)
Units on a scaleOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in FACT-An Scale Score (Quality of Life)-Part B in the Absence of Intercurrent Events (ICEs)29.20 ± 19.11339.50 ± 29.771
SecondaryChange From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange). The FACIT-F subscale is used to measure fatigue and its impact upon daily activities and function in patients with chronic illnesses and contains 20 items related to the impact of fatigue. Each item is scored on a 0-4 scale, with some items reverse-scored. Total scores range from 0 to 52, where higher scores indicate less fatigue and better outcomes, and lower scores reflect greater fatigue. It can be used alone or with other FACIT subscales as part of broader quality of life assessments.

Time frame:
Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).
Units on a scaleOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Change From Baseline to Week 48 in FACIT-F Subscale Score-Part B in the Absence of Intercurrent Events (ICEs).11.82 ± 11.25221.75 ± 14.315
SecondaryChange From Baseline to Week 48 in EQ-5D-5L-Part B in the Absence of Intercurrent Events (ICEs).

The EQ-5D-5L measures total health across 5 dimensions: Mobility, Self-care, Usual Activities, Pain/Discomfort, and Anxiety/Depression-each scored from 1 (no problems) to 5 (extreme problems). Scores form a 5-digit health profile (e.g., 12345). Each individual score plus a VAS for perceived health status today are separately reported. Higher scores reflect better total health. The EQ VAS is a patient-rated score from 0 (worst) to 100 (best health). The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange).

Time frame:
Week 48
Reported as:
Mean · Units on a scale
Change From Baseline to Week 48 in EQ-5D-5L-Part B in the Absence of Intercurrent Events (ICEs).
Units on a scaleOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Mobility-Part B0.60 ± 1.1741.25 ± 1.708
Self-care-Part B0.10 ± 0.3161.25 ± 0.957
Usual activities-Part B0.70 ± 0.9490.75 ± 1.258
Pain/Discomfort-Part B0.40 ± 0.9661.00 ± 1.414
Anxiety/Depression-Part B0.30 ± 0.4830.00 ± 1.414
SecondaryChange From Baseline to Week 48 in SF-12-Part B in the Absence of Intercurrent Events (ICEs).

The ICEs of interest were : * Withdrawal from treatment or lost to follow-up before the end of the double-blind period * Use of prohibited medications (rituximab alone or in combination, any other complement inhibitor, any other investigational drug, and plasma exchange SF-12 is a 12-item health survey assessing physical and mental health. Higher scores mean better health with scores above 50 indicating better than average health. It produces two summary scores: the Physical Component Summary (PCS) and Mental Component Summary (MCS), both norm-based (mean = 50, SD =10), with ranges of \~5-80 (PCS) and \~-3.3-80 (MCS). Higher scores = better health. It also covers 8 subscales-Physical Functioning (PF), Role-Physical (RP), Bodily Pain (BP), General Health (GH), Vitality (VT), Social Functioning (SF), Role-Emotional (RE), and Mental Health (MH), each scored between 0-100, where higher=better functioning. Scores are computed using weighted formulas from item responses (not simple averages).

Time frame:
Week 48
Reported as:
Mean · units on a scale
Change From Baseline to Week 48 in SF-12-Part B in the Absence of Intercurrent Events (ICEs).
units on a scaleOpen-label Pegcetacoplan During Part BOpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan During Part A) During Part B
Physical Component Score at Week 487.70 ± 8.31814.49 ± 9.197
Mental Component Score at Week 483.93 ± 12.4654.10 ± 8.606

Adverse events

Collected over Through study completion and follow-up for up to 104 weeks (24 months approximately).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegcetacoplan Double Blind During Part A1/16 (6.3%)5/16 (31.3%)16/16 (100%)
Placebo Matching Pegcetacoplan-Double-blind During Part A0/8 (0%)1/8 (12.5%)8/8 (100%)
Open-label Pegcetacoplan During Parts B and C0/14 (0%)6/14 (42.9%)12/14 (85.7%)
Open-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C0/7 (0%)1/7 (14.3%)4/7 (57.1%)
Most frequent serious events
Showing 10 of 15
Most frequent serious events
EventPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part AOpen-label Pegcetacoplan During Parts B and COpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C
Autoimmune haemolytic anaemiaBlood and lymphatic system disorders0/160/81/141/7
Cold type haemolytic anaemiaBlood and lymphatic system disorders0/160/82/140/7
Covid-19Infections and infestations0/161/80/140/7
Acute kidney injuryRenal and urinary disorders0/160/81/140/7
Atrial fibrillationCardiac disorders0/160/81/140/7
Breakthrough haemolysisBlood and lymphatic system disorders0/160/81/140/7
Cardiac failureCardiac disorders0/160/81/140/7
HaemolysisBlood and lymphatic system disorders0/160/81/140/7
Osteonecrosis of jawMusculoskeletal and connective tissue disorders0/160/81/140/7
Covid-19 pneumoniaInfections and infestations1/160/80/140/7
Most frequent other events
Showing 10 of 100
Most frequent other events
EventPegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part AOpen-label Pegcetacoplan During Parts B and COpen-label Pegcetacoplan (Placebo Matching Pegcetacoplan during Part A) During Parts B&C
Oedema peripheralGeneral disorders3/163/80/140/7
DyspnoeaRespiratory, thoracic and mediastinal disorders0/162/80/140/7
Covid-19Infections and infestations3/161/83/140/7
Cold type haemolytic anaemiaBlood and lymphatic system disorders2/160/83/140/7
FatigueGeneral disorders3/160/80/140/7
Upper respiratory tract infectionInfections and infestations3/160/81/140/7
Gait disturbanceGeneral disorders0/160/80/141/7
PneumoniaInfections and infestations1/160/82/140/7
CystitisInfections and infestations0/160/80/141/7
InfluenzaInfections and infestations0/161/80/141/7

Baseline characteristics

All demographic characteristics are characterized by treatment group for Parts A (placebo and pegcetacoplan along with the totals) and B (total). Part A was double blinded and Part B was open-label.

Age, Categorical
Age, Categorical(Participants)Pegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part ATotal
<=18 years000
Between 18 and 65 years314
>=65 years13720
Sex: Female, Male
Sex: Female, Male(Participants)Pegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part ATotal
Female6612
Male10212
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Pegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part ATotal
American Indian or Alaska Native000
Asian404
Native Hawaiian or Other Pacific Islander000
Black or African American000
White12820
More than one race000
Unknown or Not Reported000
Disease History-Time since diagnosis
Disease History-Time since diagnosis(Years)Pegcetacoplan Double Blind During Part APlacebo Matching Pegcetacoplan-Double-blind During Part ATotal
Mean6.0 ± 5.097.0 ± 8.606.3 ± 6.30
08

Study locations

44 sites
  • The Oncology Institute of Hope and Innovation
    Whittier, California 90603, United States
  • Lakes Research
    Miami Lakes, Florida 33014, United States
  • University of Iowa Hospitals & Clinics - The Hemophilia Treatment Center (HTC)
    Iowa City, Iowa 52242, United States
  • Weill Cornell Medicine / NewYork Presbyterian Hospital
    New York, New York 10021, United States
  • East Carolina University Division of Hematology/ Oncology
    Greenville, North Carolina 27858, United States
  • Medical University
    Vienna, Austria
  • Algemeen Ziekenhuis Klina
    Brasschaat, 2930, Belgium
  • UZ Gasthuisberg
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • St. Michael's Hospital
    Toronto, Canada
  • Helsinki University Hospital - Comprehensive Cancer Center
    Helsinki, Finland
  • "LTD Medinvest Institute of Hematology and Transfusiology "
    Tbilisi, Georgia
  • Ltd M. Zodelava Hematology Centre
    Tbilisi, Georgia
  • Universitätsklinikum Essen Klinik f. Hämatologie - Westdeutsches Tumorzentrum
    Essen, 45147, Germany
  • Institut f. Transfusionsmedizin - Universität Ulm
    Ulm, Germany
  • Semmelweis Egyetem
    Budapest, Hungary
  • A.O.R.N. S.G. Moscati di Avellino
    Avellino, 83100, Italy
  • ASST degli Spedali Civili di Brescia_Presidio Ospedaliero di Brescia_U.O. Ematologia
    Brescia, 25123, Italy
  • &#34;FOND IRCCS Cà Granda Ospedale Maggiore Policlinico
    Milan, Italy
  • AOU Maggiore della Carità SCDU Ematologia
    Novara, Italy
  • Azienda Ospedaliera Ospedali Riuniti ""Villa Sofia-Cervello
    Palermo, 90146, Italy
  • Grande Ospedale Metropolitano ""Bianchi - Melacrino - Morellii
    Reggio Calabria, 89133, Italy
  • Fukushima Medical University Hospital
    Fukushima, Japan
  • University of Tsukuba Hospital
    Ibaraki, Japan
  • Ishikawa Prefectural Central Hospital
    Kanazawa, 9208530, Japan
  • Aichi Medical University Hospital
    Nagakute, 480-1195, Japan
  • Shinshu University Hospital
    Nagano, Japan
  • Osaka University Hospital
    Osaka, 5650871, Japan
  • Amsterdam UMC
    Amsterdam, Netherlands
  • Haukeland University Hospital
    Bergen, Norway
  • Sykehuset Østfold Kalnes
    Grålum, Norway
  • St Olavs Hospital, Avdeling for blodsykdommer
    Trondheim, Norway
  • Hospital Clinic de Barcelona
    Barcelona, Spain
  • Hospital Universitario de Gran Canaria Dr. Negrin
    Las Palmas de Gran Canaria, Spain
  • Hospital Clínico Universitario de Salamanca
    Madrid, Spain
  • Hospital Universitario Infanta Leonor
    Madrid, Spain
  • Hospital Universitario La Paz
    Madrid, Spain
  • Hospital Universitario Virgen del Rocio
    Seville, Spain
  • Hospital Universitario y Politecnico La Fe
    Valencia, Spain
  • St James' University Hospital
    Leeds, LS9 7TF, United Kingdom
  • Royal London Hospital
    London, E1 2ES, United Kingdom
  • Cancer Clinical Trials Unit, Haematology -University College London -
    London, United Kingdom
  • Russell Centre for Clinical Haematology
    Nottingham, NG5 1PB, United Kingdom
  • Churchill Hospital
    Oxford, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2022 to primary completion in May 2024, 19 months.

Results were first posted in Oct 2025, 1 year 5 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 15, 2021
First posted
Oct 27, 2021
StartActual
Oct 20, 2022
Primary completionActual
May 27, 2024
CompletionActual
Sep 11, 2024
Results first posted
Oct 30, 2025
Last update
Oct 30, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05096403
Responsible party
Sponsor
First posted
Oct 27, 2021
Start date
Oct 20, 2022
Primary completion
May 27, 2024
Completion
Sep 11, 2024
Results posted
Oct 30, 2025
Last update
Oct 30, 2025

Study contacts

Study physician
study director · Swedish Orphan Biovitrum

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Pegcetacoplan

Start the discussion